共 169 条
[41]
Mitchell JA(2002)Cutaneous manifestations of inflammatory bowel disease improve with infliximab therapy [abstract] Gastroenterology 122 A618-A618
[42]
Fairclough PD(2002)Successful treatment of IBD-associated pyoderma gangrenosum with infliximab [abstract] Gastroenterology 122 A168-A168
[43]
Cipolla G(2001)Hemostatic imbalance in active and quiescent ulcerative colitis Am J Gastroenterol 96 487-493
[44]
Crema F(2003)Low vitamin B(6) plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants Am J Gastroenterol 98 112-117
[45]
Sacco S(1998)High prevalence of hyperchomocysteinemia in patients with inflammatory bowel disease: a pathogenic link with thromboembolic complications? Thromb Haemost 80 542-545
[46]
Braun J(2000)Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? Am J Gastroenterol 95 2825-2830
[47]
Sieper J(2001)Extraintestinal complications of inflammatory bowel disease Curr Treat Option Gastroenterol 4 227-243
[48]
van der Horst-Bruinsma IE(2002)Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines Gut 51 536-539
[49]
Clegg DO(2000)Infliximab and methotrexate in the treatment of rheumatoid arthritis N Engl J Med 434 1594-1602
[50]
Dijkmans BA(1999)Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs JAMA 282 1929-1933